Background
==========

Embryonic stem (ES) cells were first derived from the blastocysts of mice in 1981 \[[@B1],[@B2]\] and humans in 1998 \[[@B3]\]. ES cells have two important properties: theability to maintain pluripotency, which is the ability to differentiate into a wide variety of cells, and rapid proliferation. These characteristics make mouse ES cells an essential component of gene targeting technology. These qualitiesalso make human ES cells attractive sources for cell transplantation therapy to treat various diseases, including spinal cord injuries and juvenile diabetes. The molecular mechanisms underlying the pluripotency and rapid proliferation of ES cells are currently a major focus of the field of stem cell biology \[[@B4]-[@B6]\].

To identify molecules essential in ES cells for these properties, several groups have utilized transcriptome analyses to identify genes specifically expressed in ES cells and early embryos. These analyses, including DNA microarray analyses \[[@B7]\] and expressed sequence tag analyses \[[@B8]-[@B12]\], identified several common transcripts, including *ESG1*that was also designated *dppa5*or *ECAT2*.

ESG1 was originally identified as a transcript Ph34 that was down-regulated by retinoic acid in embryonic carcinoma cells \[[@B13]\]. The expression of this gene was confined in mice to early embryos and germ cells \[[@B14]\]. It is also expressed in pluripotent cells, including ES cells, embryonic germ cells, and multipotent germline stem cells \[[@B15]\]. *ESG1*encodes a polypeptide of 118 amino acids that contains a single KH domain, which is an RNA-binding domain \[[@B16]\]. It remains unclear, however, if ESG1 functions as an RNA-binding protein or the roles it plays in ES cells and mice.

Previous genomic library screening by identified genomic clones containing the mouse *ESG1*gene and seven pseudogenes \[[@B17]\]. Two of these pseudogenes exhibit a similar exon-intron structure as the *ESG1*gene, indicating their generation by gene duplication. The five remaining pseudogenes did not contain any introns, indicating that these were generated by retrotransposition of *ESG1*transcripts. The chromosomal localizations of the mouse *ESG1*gene and pseudogenes, however, have not been reported.

In this study, we determined the structure of the mouse gene encoding this protein and related pseudogenes. We also performed gene targeting to determine the physiological function of ESG1.

Results and discussion
======================

Chromosomal localization and structures of mouse *ESG1*gene and psedogenes
--------------------------------------------------------------------------

To determine the chromosomal localizations of the mouse *ESG1*gene and pseudogenes, we performed a Blast analysis of the mouse genomic database with the *ESG1*cDNA sequence as a query. We identified several putative pseudogenes without introns on chromosomes 1, 5, 11, 12, 14, 16, 17, and X (Figure [1](#F1){ref-type="fig"}). In addition, two intron-less pseudogenes were identified in DNA fragments for which the chromosomal localization remained unmapped. While these pseudodgenes have significant homology to *ESG1*cDNA, they could not produce functional proteins, because of critical mutations. This result suggests that there are a larger number of intron-less pseudogenes than previously anticipated. Existence of multiple retropseudogenes is a hallmark of pluripotent cell-specific genes \[[@B18]\].

![***ESG1*pseudogenes identified by a Blast search of mouse genomic databases**. Substitution mutations are indicated by black lines. Intron-like gap sequences are indicated with triangles. Chromosomal localizations are shown on the right.](1471-213X-6-11-1){#F1}

On chromosome 9, we identified a DNA fragment similar to the *ESG1*gene that included two putative introns. These putative first and second exons, however, contained (4) multiple mutations of the *ESG1*cDNA sequence. The putative third exon was identical to that of the previously reported *ESG1*gene. Also on chromosome 9, we identified another DNA fragment that was similar, but not identical, to the third exon of the ESG1 gene. These findings suggest that these *ESG1*-like sequences on chromosome 9 have not been correctly assembled.

To obtain DNA fragments containing the *ESG1*gene, we screened the bacterial artificial chromosome (BAC) DNA pool by PCR using primer pairs that would only amplify the real gene, not the pseudogenes. We obtained two independent, but overlapping BAC clones. Southern blot analyses and sequencing demonstrated that these clones contained a sequence exhibiting complete identity with *ESG1*cDNA that was interrupted by two putative introns (Figure [2A](#F2){ref-type="fig"}). The two intron sequences begin with GT and terminate with AG, fulfilling the GT-AG rule of exon-intron junctions \[[@B19]\]. The 5\' flanking region of this DNA fragment exhibited strong promoter/enhancer activity by luciferase reporter assays in undifferentiated ES cells, but not in somatic cells (Figure [3](#F3){ref-type="fig"}). The same fragment showed much weaker activity after induction of differentiation by retinoic acid. We concluded that this sequence is the *ESG1*gene.

![**BAC clones containing the *ESG1*gene and a duplication pseudogene (PS)**. A) Localization of the gene and PS on chromosome 9. B) Sequence comparison of the gene and PS revealed that these are homologous from eight base pairs upstream of the first exon to 675 bp downstream of the third exon. Substitution mutations are indicated by black lines. The insertion is indicated by an open triangle.](1471-213X-6-11-2){#F2}

![**Promoter/enhancer activity of the *ESG1*gene and pseudogene**. DNA fragments of \~6 kbp isolated from the 5\' flanking regions of the gene and PS were transferred into luciferase reporter plasmids. We introduced the reporter genes into undifferentiated ES cells (open columns), retinoic acid-treated ES cells (grey columns), and NIH3T3 cells (closed columns). Data represent the averages and standard deviations of three independent experiments.](1471-213X-6-11-3){#F3}

We also found that the two BAC clones contained another *ESG1*-like sequence (Figure [2A](#F2){ref-type="fig"}). The two sequences, separated by a 68 kbp intergenic sequence, were oriented in opposite directions. The *ESG1*-like sequence exhibited greater than 95% identity to the exons and introns of the *ESG1*gene. This sequence, however, contained critical nucleotide substitutions in all of the exons and one nucleotide insertion in exon 2 (Figure [2B](#F2){ref-type="fig"}). Although 675 base pairs of the 3\' flanking regions were conserved between the ESG1 gene and the pseudogene, only five base pairs of the 5\' flanking region were identical. This 5\' flanking region (\~6 kbp) did not possess any promoter/enhancer activity in luciferase reporter assays (Figure [3](#F3){ref-type="fig"}). It is thus unlikely that this sequence is transcribed or translated into a functional protein. This sequence likely represents a duplication pseudogene. Bierbaum previously reported the existence of two pseudogenes with similar exon-intron organization as the *ESG1*gene \[[@B17]\]. We could not determine which of these two pseudogenes corresponds to the one we identified or the location of the remaining pseudogene.

Targeted disruption of the mouse *ESG1*gene
-------------------------------------------

To study the function of ESG1, we deleted the gene by homologous recombination in mouse ES cells. We replaced the three exons with either a fusion of the neomycin-resistance and β-galactosidase genes (β-geo) or the hygromycin resistant gene (HygR) using two targeting vectors (Figure [4A](#F4){ref-type="fig"}) introduced into RF8 ES cells by electroporation. We obtained eight ES cell clones with correct homologous recombination of the β-geo targeting vector, which was confirmed by Southern blot analysis (Figure [4B](#F4){ref-type="fig"}). We obtained only one clone with correct homologous recombination of the HygR targeting vector.

![**Targeted disruption of the mouse ESG1 gene**. A) Targeting strategy. Homologous regions are indicated by thick lines. Recognition sites of *Pst*I (P) and *Spe*I (S), which were used for Southern blot analyses, are shown. The gene encoding diphtheria toxin A (DTA) was inserted at the 3\' end of the targeting vectors to facilitate negative selection. B) Southern blot analyses confirming homologous recombination. WT, wild-type ES cells; β, β-geo +/- ES cells; H, HygR +/- ES cells; -/-, ESG1-null ES cells. Numbers indicate clone numbers. C) Northern blot (upper) and western blot (lower) analyses of wild-type ES cells (WT), ESG1-null ES cells (-/-, three clones) and heterozygous ES cells (+/-). Northern blot was performed as previously described \[20\]. To confirm the loading of equal amounts of RNA, ethidium bromide staining of ribosomal RNA is also shown (middle).](1471-213X-6-11-4){#F4}

To obtain homozygous mutant ES cells, we introduced the β-geo vector into HygR heterozygous ES cells. Of 105 G418-resistant colonies tested, 49 were homozygous for *ESG1*deletion. Northern blot and western blot analyses confirmed the absence of ESG1 in these cells (Figure [4C](#F4){ref-type="fig"}). In 29 clones, the β-geo vector had replaced the HygR vector, such that the cells remained heterozygous. In the remaining 27 clones, the β-geo vector was integrated at non-homologous sites.

*ESG1*^-/-^ES cells exhibited normal morphology (Figure [5A](#F5){ref-type="fig"}). These cells also proliferated at a speed comparable to that of the control (heterozygous and wild-type) cells (Figure [5B](#F5){ref-type="fig"}). *ESG1*^-/-^cells differentiated normally after the removal of leukemia inhibitory factor (Figure [5B](#F5){ref-type="fig"}) or retinoic acid treatment (not shown). When transplanted into hind flanks of nude mice, these cells produced teratomas, tumors containing components of all three germ layers (Figure [5C](#F5){ref-type="fig"}). These results indicate that ESG1 is dispensable for the self-renewal properties and pluripotency of ES cells.

![**Analyses of ESG1-null ES cells**. A) The morphology of ESG1-null ES cell colonies grown on STO feeder cells. B) Growth curve of wild-type (WT), ESG1-null (-/-) and heterozygous (+/-) ES cells. Each clone (1 × 10^4^cells/well) was plated in 24-well plates. Cell numbers were determined with a Coulter counter at 2, 4, and 6 days. Data of +/- and -/- cells are shown as averages and standard deviations of three independent clones. C) A section of teratoma derived from ESG1-null ES cells (hematoxylin & eosin staining).](1471-213X-6-11-5){#F5}

We examined the gene expression profiles of *ESG1*^-/-^ES cells using oligonucleotide-based DNA microarrays representing \~20,000 genes. In comparison to control ES cells, *ESG1*was identified as the gene reduced to the greatest extent in *ESG1*^-/-^ES cells (Figure [6A](#F6){ref-type="fig"}). The expression of ES cell marker genes, such as *Nanog*and *Oct3/4*, was normal in *ESG1*^-/-^ES cells. We confirmed normal Oct3/4 expression at protein levels by Western blot (Figure [6B](#F6){ref-type="fig"}). The overall gene expression profiles were similar between control ES cells and *ESG1*^-/-^ES cells. Several genes exhibited a greater than two-fold reduction in *ESG1*^-/-^cells, including *Krt1-8, Pem, Ctgf, Ptgs2, Igf2 and Inhba*. These genes might be regulated directly or indirectly by ESG1. Since ESG1 contains a KH-type RNA-binding domain, it may stabilize mRNA of these genes. Further studied are required to clarify this possibility.

![**Gene expression analyses of ESG1-null ES cells**. A) DNA microarray analyses. Total RNA from wild-type ES cells and ESG1-null ES cells were labeled with Cy3 and Cy5, respectively. Samples were hybridized to Agilent Mouse Developmental Microarrays. The averages of two independent clones are shown. B) Western blot analyses. Cell lysates from ESG1^+/-^and ESG1^-/-^cells were examined for expression of ESG1, Oct3/4 and CDK4 with immunoblotting.](1471-213X-6-11-6){#F6}

To generate ESG1-knockout mice, we injected β-geo-*ESG1*^+/-^ES cell clones into the blastocysts of C57BL6 mice. We obtained germline transmission from three clones. We obtained *ESG1*^-/-^mice at the Mendelian ratios (36 wild-type, 69 *ESG1*^+/-^, and 45 *ESG1*^-/-^) from intercrosses of *ESG1*^+/-^mice. These animals exhibited normal development, gross appearance, and fertility (not shown). Histological examination of testis and ovary could not identify any abnormalities (not shown). These data demonstrated that ESG1 is dispensable for both mouse development and germ cell formation.

We also generated ES cells from blastocysts obtained by intercrosses of *ESG1*^+/-^males and *ESG1*^-/-^females. Of the eight ES cell lines established, two clones were *ESG1*^-/-^. These ESG1-null ES cells demonstrated normal morphology, proliferation, and differentiation (not shown), confirming that ESG1 is dispensable in ES cells.

Conclusion
==========

To analyze the physiological roles of ESG1, we identified the mouse gene on chromosome 9 and deleted it by homologous recombination in ES cells. Despite specific expression in early embryos, germ cells, and pluripotent cells, our data demonstrated that ESG1 is dispensable for mouse development, germ cell formation, and ES cell self-renewal.

Methods
=======

Identification and analyses of BAC clones containing the mouse *ESG1*gene
-------------------------------------------------------------------------

To identify bacterial artificial chromosome (BAC) clones containing mouse *ESG1*gene, we performed PCR-based screening of mouse BAC library DNA pools (Research Genetics) using the pH34-u38 (5\'-GAAGTCTGGTTCCTTGGCAGG-3\') and pH34-L394 (5\'-ACTCGATACACTGGCCTAGC-3\') primers. Following restriction enzyme digestion, we performed Southern blot analyses of BAC clones as described \[[@B20]\] using the pH34-U258 (5\'-CTCGAGTGTACAGTCAAGTGGTTGCTGGGA-3\'), pH34-U65 (5\'-GTGACCCTCGTGACCCGTAA-3\'), pH34-intron1L (5\'-CTGCGTGAGAGAAACACCAAACAGGC-3\'), pH34-L545 (5\'-TGTGAATGGGAAGGTTACCACTCT-3\') and pH34-SCL1 (5\'-GCCCTCTTCTGGTTTGTCTCGAAAT-3\') probes. Hybridization with these probes revealed bands containing either the *ESG1*gene or pseudogenes.

To sequence the region containing the mouse *ESG1*gene and the 3\' flanking region, we subcloned a \~15 kbp *Xho*I-*Sal*I fragment into the pZERO-2 vector (Invitrogen). *Hind*III- or *EcoR*I-digested fragments of this vector were then cloned into pBluescript KS(-) for sequencing. To sequence the *ESG1*pseudogene and the 3\' flanking region, an 8 kbp *Not*I/*Xho*I fragment was cloned into pBluescript KS(-). *BamH*I- or *Pst*I- fragments of this vector were also cloned into pBluescript KS(-). To identify the sequence containing the 5\' flanking regions of the *ESG1*gene and the related pseudogenes, we used a TOPO walker kit (Invitrogen) with the pH34-T2L (5\'-ACTAGTCGCAGCAGGGATCCAGGAATATCT-3\') and pH34-L394 primers. The resulting sequence was cloned into pCR2.1 (Invitrogen). We obtained a \~6 kbp band from the *Nsi*I-digensted library; *Xba*I-, *Spe*I-, *EcoR*I-, and *Pst*I-digested fragments of this band were cloned into pBluescript KS(-) for sequencing. This fragment contained the 5\' flanking region of the *ESG1*gene. A \~3 kbp fragment, obtained from the *Sac*I-digested library, was cloned into pCR2.1 for sequencing. This fragment was contained the 5\' region flanking the pseudogene.

Construction of *ESG1*targeting vectors
---------------------------------------

We replaced all of the *ESG1*exons with two targeting vectors containing either an IRES-β-geo cassette \[[@B21]\] or an IRES-HygR cassette by promoter trap selection. We amplified the 5\' arm (1.8 kbp) using KOD plus (TOYOBO) with the pH34-targetpair5-U (5\'-CCGCGGAAAGTCAAGAGATTGGGTGG-3\') and pH34-targetpair5-L (5\'-GCGGCCGCCTTTACGGGTCACGAGGGTCAC-3\') primers. The 3\' arm (5.8 kbp) was amplified using the pH34-targetpair3-U (5\'-TGTGGCCAGTGTTTGGTTCTGGCGGG-3\') and pH34-targetpair3-L (5\'-CTCGAGGACTCGCCATTCTAGCCAAG-3\') primers. The IRES β-geo or IRES HygR cassettes were ligated in between the two PCR fragments. The diphtheria toxin A cassette was placed downstream of the 3\' arm. After linearization with *Sac*II, these targeting vectors were electroporated into 2.0 × 10^7^RF8 ES cells \[[@B22]\] using a Gene pulser (BIORAD). Transfected cells were selected with 250 μg/mL G418 or 100 μg/mL hygromycin B, respectively. Genomic DNA from G418- or hygromycin B-resistant colonies was screened for homologous recombination by Southern blotting.

Southern blot screening for homologous recombination
----------------------------------------------------

ES cells genomic DNA was extracted with PUREGENE™ Cell Lysis Solution (Gentra systems). For 5\' Southern blot analysis, genomic DNA was first digested with *Pst*I, then separated on an 0.8% agarose gel and transferred to a nylon membrane as described \[[@B20]\]. A 560 bp 5\' probe was amplified using the ESG1S5 (5\'- GATGGTGGTGGTGACTCAGAG -3\') and ESG1AS5 as (5\'- CCTCCATTGCCTCTATATCAG -3\') primers. The probe specifically labeled an 18 kbp band from the wild-type locus, a 15 kbp band from the β-geo locus, and a 12 kbp band from the HygR locus. Genomic DNA was also digested with SpeI for 3\' Southern blot analysis. A 1,010 bp 3\' probe was amplified with the pH34U-8000 (5\'- CCAACCAGCCAGAGTTTCAGTTAT -3\') and pH34L-9000 (5\'-GATAAGCTGCTGCCAAAAGACAAG -3\') primers. The probe hybridized to an 11.5 kbp band from the wild-type locus, a 12.5 kbp band from the β-geo locus, and a 9.5 kbp band from the HygR locus.

Generation of anti-ESG1 polyclonal antibodies
---------------------------------------------

The coding sequence of *Esg1*was amplified by PCR with the pH34-gw-s (5\'- AAAAAGCAGGCTGGATGATGGTGACCCTCGTGA-3\') and pH34-gw-as (5\'- AGAAAGCTGGGTCTGCATCCAGGTCGGAGACA-3\') primers. To construct pDONR-pH34, the resulting PCR product was subcloned into pDONR201 (Invitrogen). pDONR-pH34 was interacted with pDEST17 (Invitrogen) by LR recombination. After introduction of the resulting expression vector pDEST17-pH34 into BL21-AI *E. coli*(Invitrogen), recombinant protein production was induced according to the manufacture\'s protocol. Histidine-tagged ESG1 was purified using Ni-nitrilotriacetic acid agarose (Qiagen) under denaturing conditions in the presence of 8 M urea. After dialysis against 6 M urea, the recombinant proteins were injected into New Zealand White rabbits to generate anti-ESG1 polyclonal antibodies.

Western blot
------------

After preparation of ES cell extracts with M-Per (Pierce), cellular proteins were separated on sodium dodecyl sulfate (SDS)-14% polyacrylamide gels and transferred to nitrocellulose membranes (Millipore). Membranes were incubated with anti-ESG1 (1/500 dilution), anti-Oct3/4 (1/500; Santa Cruz Biotechnology), anti-CDK4 (1/200; Santa Cruz Biotechnology), and anti-GFP (1/1000; MBL) primary antibodies. Horseradish peroxidase-conjugated anti-rabbit and anti-mouse immunoglobulins (1/5000; Cell Signaling) were used to detect antibody binding. We visualized bound antibody with an ECL Western Blotting Detection System (Amersham).

Derivation of ESG1-deficient ES cells from blastocysts
------------------------------------------------------

*Esg1*^+/-^*or ESG1*^-/-^mutant female mice were injected with Tamoxifen (10 μg) and Depo-provera (1 mg) subcutaneously on the third day of pregnancy. Four days later, embryos in diapause were flushed out of the uterus and cultured on STO feeder cells in four-well plates in Dulbecco\'s Modified Eagle Medium (DMEM) supplemented with 20% Fetal Bovine Serum (Hyclone), 0.1 mM Non-Essential Amino Acids (Invitrogen), 2 mM L-glutamine (Invitrogen), 50 U/ml Penicillin-Streptomysin (Invitrogen), and 0.11 mM 2-mercaptoethanol (Invitrogen). After six days, the central mass of each explant was harvested, rinsed in PBS, and placed in a drop of trypsin for a few minutes. The cell mass was collected with a finely drawn-out Pasteur pipette preloaded with medium, ensuring minimal carryover of the trypsin. The cells were gently transfered into a fresh well with 20% FBS-containing medium. The resulting primary ES cell colonies were individually passaged into wells of four-well plates containing STO feeder cell layers. Thereafter, cells were expanded by trypsinization of the entire culture.

Microarrays
-----------

Total RNA from wild-type ES cells and ESG1^-/-^ES cells was labeled with Cy3 and Cy5, respectively. The samples were hybridized to a Mouse Development Microarray (Algilent) according to the manufacturer\'s protocol. Arrays were scanned with a G2565BA Microarray Scanner System (Agilent). Hybridization was repeated with two independent clones. Data were analyzed with GeneSprings software (Silico Genetics).
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